Spinraza

E24879

Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.

AI illustration

How this image was made

AI-generated illustration of Spinraza

This AI-generated illustration was produced by black-forest-labs/FLUX.2-dev (1024x1024) from a prompt written by openai/gpt-oss-120b from the entity's label + description.

Prompt

Generate an image of a spinraza (Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.)

All labels observed (3)

Label Occurrences
nusinersen 7
Spinraza canonical 4
SMN2 1

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf antisense oligonucleotide ⓘ
biologic medicinal product ⓘ
medication ⓘ
orphan drug ⓘ
prescription drug ⓘ
approvedBy European Medicines Agency ⓘ
U.S. Food and Drug Administration ⓘ
developedBy Biogen ⓘ
Ionis Pharmaceuticals ⓘ
hasActiveIngredient nusinersen ⓘ
linked to: Spinraza
hasAdministrationSite cerebrospinal fluid ⓘ
hasATCCode M09AX07 ⓘ
hasBrandOwner Biogen ⓘ
hasCommonAdverseEffect back pain ⓘ
constipation ⓘ
headache ⓘ
nausea ⓘ
respiratory infection ⓘ
hasDosageForm solution for injection ⓘ
hasGenericName nusinersen ⓘ
linked to: Spinraza
hasInternationalNonproprietaryName nusinersen ⓘ
linked to: Spinraza
hasLoadingDoseRegimen four loading doses over approximately two months ⓘ
hasMaintenanceDoseRegimen one dose every four months ⓘ
hasPregnancyCategory not assigned; use only if potential benefit justifies potential risk ⓘ
hasSeriousAdverseEffect coagulation abnormalities ⓘ
renal toxicity ⓘ
thrombocytopenia ⓘ
hasTherapeuticArea neurology ⓘ
rare diseases ⓘ
increasesProductionOf SMN protein ⓘ
survival motor neuron protein ⓘ
indicatedFor adult patients with spinal muscular atrophy ⓘ
pediatric patients with spinal muscular atrophy ⓘ
isAdministeredBy healthcare professional ⓘ
isFirstDrugApprovedFor spinal muscular atrophy ⓘ
isUsedAs disease-modifying therapy for spinal muscular atrophy ⓘ
legalStatusInEuropeanUnion prescription only ⓘ
legalStatusInUnitedStates prescription only ⓘ
mechanismOfAction antisense oligonucleotide that modulates SMN2 pre-mRNA splicing ⓘ
modifiesGeneExpression SMN2 ⓘ
regulatoryApprovalYear 2016 ⓘ
requiresMonitoringOf coagulation parameters ⓘ
platelet count ⓘ
renal function ⓘ
routeOfAdministration intrathecal ⓘ
lumbar puncture ⓘ
targetsGene SMN2 ⓘ
linked to: Spinraza
treats 5q spinal muscular atrophy ⓘ
spinal muscular atrophy ⓘ

How these facts were elicited

Referenced by (12)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen → hasProduct → Spinraza ⓘ
Biogen → hasNotableDrug → Spinraza ⓘ
Spinraza → hasGenericName → nusinersen ⓘ
linked to: Spinraza
Spinraza → hasInternationalNonproprietaryName → nusinersen ⓘ
linked to: Spinraza
Spinraza → hasActiveIngredient → nusinersen ⓘ
linked to: Spinraza
Spinraza → targetsGene → SMN2 ⓘ
linked to: Spinraza
spinal muscular atrophy → treatedBy → nusinersen ⓘ
linked to: Spinraza
SMN2 → targetOfDrug → nusinersen ⓘ
linked to: Spinraza
JEWELFISH → includesPriorTherapy → nusinersen ⓘ
linked to: Spinraza
RNA therapeutics → regulatoryApprovedExample → nusinersen ⓘ
linked to: Spinraza